{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:41:46Z","timestamp":1792644106368,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82522079"],"award-info":[{"award-number":["82522079"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82674836"],"award-info":[{"award-number":["82674836"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119327","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:25:25Z","timestamp":1789665925000},"page":"119327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From discovery to clinic: Medicinal chemistry strategies for PROTAC linker optimization"],"prefix":"10.1016","volume":"320","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7744-411X","authenticated-orcid":false,"given":"Hongjin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qidong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8181-5644","authenticated-orcid":false,"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119327_bib1","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/acscentsci.3c00395","article-title":"Proximity-based modalities for biology and medicine","volume":"9","author":"Liu","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2026.119327_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119327_bib3","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119327_bib4","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: from mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119327_bib5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2015.06.023","article-title":"The ubiquitin\u2013proteasome system and its potential application in hepatocellular carcinoma therapy","volume":"379","author":"Chen","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.119327_bib6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.aax3769","article-title":"Cellular quality control by the ubiquitin-proteasome system and autophagy","volume":"366","author":"Pohl","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119327_bib7","article-title":"Targeted protein degradation in cancers: orthodox PROTACs and beyond","volume":"4","author":"Li","year":"2023","journal-title":"Innovation"},{"key":"10.1016\/j.ejmech.2026.119327_bib8","series-title":"Targeted Protein Degradation: Methods and Protocols","year":"2021"},{"key":"10.1016\/j.ejmech.2026.119327_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119327_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400171","article-title":"Structural basis of conformational dynamics in the PROTAC-Induced protein degradation","volume":"19","author":"Zhao","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119327_bib11","doi-asserted-by":"crossref","first-page":"16271","DOI":"10.1021\/acs.jmedchem.1c01576","article-title":"Integrative modeling of PROTAC-mediated ternary complexes","volume":"64","author":"Weng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119327_bib12","doi-asserted-by":"crossref","first-page":"14580","DOI":"10.1021\/acs.jmedchem.6c00527","article-title":"Linker-driven sampling of PROTAC-induced ternary complexes","volume":"69","author":"Zhao","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119327_bib13","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1038\/s41467-023-39904-5","article-title":"Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation","volume":"14","author":"Wurz","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119327_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116520","article-title":"Application and challenges of nitrogen heterocycles in PROTAC linker","volume":"273","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119327_bib15","doi-asserted-by":"crossref","first-page":"17595","DOI":"10.1039\/D5SC04859A","article-title":"Rational design of the linkers in targeting chimeras","volume":"16","author":"Duan","year":"2025","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119327_bib16","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/j.apsb.2024.04.007","article-title":"Characteristic roadmap of linker governs the rational design of PROTACs","volume":"14","author":"Dong","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119327_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acschembio.9b00092","article-title":"SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate","volume":"14","author":"Roy","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119327_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112451","article-title":"Optimal linker length for small molecule PROTACs that selectively target p38\u03b1 and p38\u03b2 for degradation","volume":"201","author":"Donoghue","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119327_bib19","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1021\/ja311795d","article-title":"A comprehensive mathematical model for three-body binding equilibria","volume":"135","author":"Douglass","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119327_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF02910016","article-title":"Properties, variants, and applications of the immunoradiometric assay method","volume":"5","author":"Miles","year":"1975","journal-title":"La Ricerca Clin. Lab."},{"key":"10.1016\/j.ejmech.2026.119327_bib21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12918-017-0447-8","article-title":"Cooperative binding mitigates the high-dose hook effect","volume":"11","author":"Roy","year":"2017","journal-title":"BMC Syst. Biol."},{"key":"10.1016\/j.ejmech.2026.119327_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) \u2014 past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejmech.2026.119327_bib23","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119327_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103917","article-title":"Exploring the chemical space of orally bioavailable PROTACs","volume":"29","author":"Apprato","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119327_bib25","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"13_Suppl","key":"10.1016\/j.ejmech.2026.119327_bib26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1538-7445.AM2021-44","article-title":"Abstract 44: the discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer","volume":"81","author":"Snyder","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119327_bib27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/d41573-019-00043-6","article-title":"First targeted protein degrader hits the clinic","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119327_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202501111","article-title":"Insights into vepdegestrant (ARV-471): the first-in-class estrogen receptor proteolysis-targeting chimera approaching food and drug administration approval for breast cancer","volume":"21","author":"Tang","year":"2026","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119327_bib29","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119327_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4155\/fmc-2021-0208","article-title":"PROTAC cell permeability and oral bioavailability: a journey into uncharted territory","volume":"14","author":"Poongavanam","year":"2022","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119327_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.101175","article-title":"Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling","volume":"15","author":"He","year":"2025","journal-title":"J. Pharm. Anal."},{"issue":"13_Suppl","key":"10.1016\/j.ejmech.2026.119327_bib32","first-page":"43","article-title":"Abstract 43: discovery of ARV-110, a first-in-class androgen receptor degrading PROTAC for the treatment of men with metastatic castration-resistant prostate cancer","volume":"81","author":"Gough","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119327_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1200\/JCO.2019.37.7_suppl.259","article-title":"ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer","volume":"37","author":"Neklesa","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119327_bib34","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3390\/molecules27061977","article-title":"Development of an LC-MS\/MS method for ARV-110, a PROTAC molecule, and applications to pharmacokinetic studies","volume":"27","author":"Nguyen","year":"2022","journal-title":"Molecules"},{"issue":"12_Suppl","key":"10.1016\/j.ejmech.2026.119327_bib35","first-page":"ND03","article-title":"Abstract ND03: discovery of ARV-766, an androgen receptor degrading PROTAC for the treatment of men with metastatic castration-resistant prostate cancer","volume":"82","author":"Gough","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119327_bib36","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1200\/JCO.2024.42.16_suppl.5011","article-title":"ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): initial results of a phase 1\/2 study","volume":"42","author":"Petrylak","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119327_bib37","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","article-title":"Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer","volume":"41","author":"Buttigliero","year":"2015","journal-title":"Cancer Treat. Rev"},{"key":"10.1016\/j.ejmech.2026.119327_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2026.119327_bib39","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1021\/acs.jmedchem.5c03138","article-title":"Discovery of AZD9750, an orally bioavailable androgen receptor degrader for the treatment of prostate cancer","volume":"69","author":"Scott","year":"2026","journal-title":"J. Med. Chem."},{"issue":"2_Suppl","key":"10.1016\/j.ejmech.2026.119327_bib40","article-title":"Abstract B046: AZD9750, a novel androgen receptor proteolysis targeting chimera (AR-PROTAC) with monotherapy and combination activity in prostate cancer","volume":"86","author":"Li","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119327_bib41","doi-asserted-by":"crossref","first-page":"8885","DOI":"10.1038\/s41467-024-52871-9","article-title":"Design of a cereblon construct for crystallographic and biophysical studies of protein degraders","volume":"15","author":"Kroupova","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119327_bib42","doi-asserted-by":"crossref","first-page":"15195","DOI":"10.1074\/jbc.RA118.003314","article-title":"Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and toll-like receptor signaling","volume":"293","author":"De Nardo","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119327_bib43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","article-title":"Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119327_bib44","doi-asserted-by":"crossref","first-page":"10548","DOI":"10.1021\/acs.jmedchem.3c01823","article-title":"Discovery of KT-413, a targeted protein degrader of IRAK4 and IMiD substrates targeting MYD88 mutant diffuse large B-cell lymphoma","volume":"67","author":"Weiss","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119327_bib45","series-title":"Proteolysis Targeting Chimeras (PROTACs) in \u2018Beyond rule-of-five\u2019 Chemical Space: Recent Progress and Future Challenges","author":"Edmondson","year":"2019"},{"key":"10.1016\/j.ejmech.2026.119327_bib46","article-title":"Phase 1 evaluation of ASP3082, a first-in-class selective protein degrader, in patients (pts) with KRAS G12D -mutant pancreatic ductal adenocarcinoma (PDAC): Pharmacokinetics (PK) and biomarker insights","volume":"44","author":"Park","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119327_bib47","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMoa2600752","article-title":"Setidegrasib in advanced non-small-cell lung cancer and pancreatic cancer","volume":"394","author":"Park","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119327_bib48","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","article-title":"Discovery of KRAS(G12D) selective degrader ASP3082","volume":"8","author":"Yoshinari","year":"2025","journal-title":"Commun. Chem."},{"key":"10.1016\/j.ejmech.2026.119327_bib49","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1021\/acs.jmedchem.4c02492","article-title":"Impact of linker composition on VHL PROTAC cell permeability","volume":"68","author":"Abeje","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119327_bib50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119327_bib51","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.119327_bib52","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119327_bib53","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","article-title":"Discovery and preclinical pharmacology of NX-2127, an orally bioavailable degrader of Bruton's tyrosine kinase with immunomodulatory activity for the treatment of patients with B cell malignancies","volume":"67","author":"Robbins","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119327_bib54","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-141461","article-title":"NX-2127, a degrader of BTK and IMiD neosubstrates, for the treatment of B-cell malignancies","volume":"136","author":"Robbins","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119327_bib55","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1158\/1538-7445.AM2023-3423","article-title":"Abstract 3423: NX-2127: a first-in-class clinical stage degrader of BTK and IKZF1\/3 for the treatment of patients with B cell malignancies","volume":"83","author":"Mihalic","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119327_bib56","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood.2022016934","article-title":"NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts","volume":"141","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119327_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119327_bib58","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1038\/s41467-022-33430-6","article-title":"A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo","volume":"13","author":"Kofink","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119327_bib59","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1158\/0008-5472.CAN-14-3798","article-title":"The SMARCA2\/4 ATPase domain surpasses the bromodomain as a drug target in SWI\/SNF-mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies","volume":"75","author":"Vangamudi","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119327_bib60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-cancerbio-061824-105806","article-title":"Development of PROTAC degrader drugs for cancer","volume":"9","author":"Vetma","year":"2025","journal-title":"Ann. Rev. Cancer Biol."},{"key":"10.1016\/j.ejmech.2026.119327_bib61","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1073\/pnas.1316793111","article-title":"Functional epigenetics approach identifies BRM\/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers","volume":"111","author":"Hoffman","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.119327_bib62","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1158\/0008-5472.CAN-25-1141","article-title":"PRT3789 is a first-in-human SMARCA2-selective degrader that induces synthetic lethality in SMARCA4-mutated cancers","volume":"86","author":"Hulse","year":"2026","journal-title":"Cancer Res."},{"issue":"12_Suppl","key":"10.1016\/j.ejmech.2026.119327_bib63","first-page":"3263","article-title":"Abstract 3263: preclinical characterization of PRT3789, a potent and selective SMARCA2 targeted degrader","volume":"82","author":"Kelly","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119327_bib64","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1021\/acschembio.0c00266","article-title":"Structural insights into PROTAC-mediated degradation of Bcl-xL","volume":"15","author":"Chung","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119327_bib65","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/1535-7163.MCT-11-0415","article-title":"The Bcl-2\/Bcl-xL\/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo","volume":"10","author":"Chen","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119327_bib66","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13046-025-03635-w","article-title":"PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models","volume":"45","author":"Valentini","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119327_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200615","article-title":"Systematic potency and property assessment of VHL ligands and implications on PROTAC design","volume":"18","author":"Krieger","year":"2023","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119327_bib68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-025-01753-8","article-title":"First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed\/refractory solid malignancies","volume":"18","author":"Mahadevan","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119327_bib69","doi-asserted-by":"crossref","first-page":"24848","DOI":"10.1021\/acs.jmedchem.5c01317","article-title":"Discovery of CFT8634, a potent, selective, and orally bioavailable heterobifunctional degrader of BRD9","volume":"68","author":"Jackson","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:23:13Z","timestamp":1792642993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":69,"alternative-id":["S0223523426007725"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119327","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From discovery to clinic: Medicinal chemistry strategies for PROTAC linker optimization","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119327","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119327"}}